Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)

Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)

BackgroundRegorafenib and trifluridine/tipiracil (FTD/TPI) ± bevacizumab are both indicated for patients diagnosed with metastatic colorectal cancer (mCRC) in the third line or later. However, in the absence of recommendations regarding preferred treatment order, our study aimed to improve the under...

Full description

Saved in:
Bibliographic Details
Main Authors: Tanios Bekaii-Saab, Ila Sruti, Junxin Shi, Wei Dai, Gregory Patton, Sreevalsa Appukkuttan, Brian Hocum, Arvind Katta, Svetlana Babajanyan, David Cosgrove
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Oncology
Subjects:
metastatic colorectal cancer
regorafenib
real world research
clinical outcomes
treatment patterns
sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1591245/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1591245/full

Similar Items